|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-2-10
|
|
pubmed:abstractText |
Infliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-TNF drugs appear to be equally efficacious in the treatment of Crohn's Disease and therefore the decision regarding which drug to choose will depend to some extent on patient choice, which may be based on the mode of administration.The aims of this study were to compare preferences in Inflammatory Bowel Disease (IBD) patients for two currently available anti-TNF agents and the reasons for their choices.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-10180362,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-12017400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-12240793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-12492201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-12501880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-14621334,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-15207890,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-15471780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-1556402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-15977463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-15987329,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-16368038,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-17085468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-17241859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-17678510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-17726671,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-18076736,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-18295023,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-18848553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-18853973,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-19035976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-19109962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-19438428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-19596014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-2644154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-8803747,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20064220-9924064
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-230X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20064220-Adult,
pubmed-meshheading:20064220-Anti-Inflammatory Agents,
pubmed-meshheading:20064220-Antibodies, Monoclonal,
pubmed-meshheading:20064220-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20064220-Drug Administration Schedule,
pubmed-meshheading:20064220-Humans,
pubmed-meshheading:20064220-Inflammatory Bowel Diseases,
pubmed-meshheading:20064220-Injections, Intravenous,
pubmed-meshheading:20064220-Injections, Subcutaneous,
pubmed-meshheading:20064220-Life Style,
pubmed-meshheading:20064220-Mesalamine,
pubmed-meshheading:20064220-Patient Compliance,
pubmed-meshheading:20064220-Patient Preference,
pubmed-meshheading:20064220-Population Surveillance,
pubmed-meshheading:20064220-Quality of Life,
pubmed-meshheading:20064220-Questionnaires,
pubmed-meshheading:20064220-Self Administration,
pubmed-meshheading:20064220-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
How do patients with inflammatory bowel disease want their biological therapy administered?
|
|
pubmed:affiliation |
Division of Gastroenterology, Ulster Hospital, Dundonald, Belfast, N Ireland BT16 1RH, UK. paddyallen8@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
